HC Wainwright Reaffirms “Buy” Rating for Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $37.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 316.20% from the company’s previous close.

Several other equities analysts have also weighed in on the company. Jefferies Financial Group began coverage on Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company. Oppenheimer cut their price target on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th.

Pharming Group Price Performance

Shares of Pharming Group stock opened at $8.89 on Tuesday. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. Pharming Group has a twelve month low of $6.65 and a twelve month high of $13.20. The business has a 50-day moving average price of $8.28 and a 200 day moving average price of $8.13. The firm has a market cap of $603.01 million, a PE ratio of -34.19 and a beta of 0.05.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in shares of Pharming Group (NASDAQ:PHAR) by 75.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.